SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

The Value of Improving the Productivity of the Drug Development Process · Study

ArticleShelves

ArticleThe Value of Improving the Productivity of the Drug Development Process

Joseph A. DiMasi2002

Article2002

The Value of Improving the Productivity of the Drug Development Process

Joseph A. DiMasi

233 citations·0/0 files stored·PharmacoEconomics

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Pharmaceutical Economics and Policy Health Systems, Economic Evaluations, Quality of Life Pharmaceutical industry and healthcare

Abstract

No abstract was published for this record.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 233 citations exist upstream.

References

2003The price of innovation: new estimates of drug development costs 1991Cost of innovation in the pharmaceutical industry 2001Risks in new drug development: Approval success rates for investigational drugs 2002Returns on Research and Development for 1990s New Drug Introductions 2001New drug development in the United States from 1963 to 1999

Cited by

2011Letting Rivals Come Close or Warding Them Off? The Effects of Substitution Threat on Imitation Deterrence 2004R&D Costs and Returns by Therapeutic Category 2008Contribution of economic evaluation to decision making in early phases of product development: A methodological and empirical review 2007Shareholder returns and the exploration–exploitation dilemma: R&D announcements by biotechnology firms 2004Antibacterial research and development in the 21st Century – an industry perspective of the challenges 2014Planning operations before market launch for balancing time-to-market and risks in pharmaceutical supply chains 2018How do patent-based measures inform product commercialization? —The case of the United States pharmaceutical industry

Related works

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

2004The Economics of Follow-on Drug Research and Developmentarticle · 4 shared references 2004R&D Costs and Returns by Therapeutic Categoryarticle · 4 shared references 2005Comment on ???The Economics of Follow-On Drug Research and Development: Trends in Entry Rates and the Timing of Development???article · 4 shared references 2007Economics of New Oncology Drug Developmentarticle · 3 shared references 2005Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliancesarticle · 3 shared references 2016Changing R&D models in research-based pharmaceutical companiesreview · 3 shared references

Details

Year2002

Typearticle

Published2002-01-01

VenuePharmacoEconomics

ISSN-L1170-7690

Languageen

Citations233

Files0 public / 0

ShelfPharmaceutical Economics and Policy

Identifiers

doi10.2165/00019053-200220003-00001

openalex_workW2018941662

Links

Imported from OpenAlex (CC0) — nothing here is generated.